Women are twice as likely as men to be diagnosed with MS and 450,000 women in Europe are affected by the condition. CRA investigated the burden of MS on women patients and the implications on Europe’s economy and society. Our research found a significant impact for women in terms of their family life, career progression and labour market role, that is not recognised by current MS polices. Our analysis suggests a need for greater awareness initiatives to drive early diagnosis and multidisciplinary treatment approaches to facilitate timely access to care. Also, social and workplace support can increase participation in the labour force and social activities, supporting women, their families and the wider economy.
CRA Insights
Re-thinking healthcare policy to reflect the disproportionate impact of MS on women
March 5, 2019
Upcoming events
Informa: EU Pharmaceutical Law Forum 2026
CRA is a proud sponsor the event featuring authority insights from the EU Commission, Competition Authorities, EMA and leading pharmaceutical...
ThoughtLeaders4: 3rd Annual UK Competition Law
CRA is a proud sponsor of the summit. Simon Chisholm is a speaker during the session titled “Understanding Lessons and Takeaways from Market Investigations”...